Search Videos and More
News
Dana-Farber Cancer Institute, Boston Children’s Hospital, and Broad Clinical Labs Launch Precision Genomics Initiative for Pediatric Cancer
In a pioneering collaboration aimed at transforming pediatric cancer diagnostics and research, Dana-Farber Cancer Institute, Boston Children’s Hospital, and Broad Clinical Labs have announced the formation of BrightSeq — Boston Research in Innovative Genomics for Hematologic and Tumor Sequencing — collaborative clinical research and testing initiative.
News
Dana-Farber Research Shows Promise for Targeted Therapies for Pediatric Gliomas
Results from this study show that already approved precision medicines have the potential benefit for children with FGFR-altered gliomas.
News
Teen with Rare Sarcoma Enjoys Stellar Response on Clinical Trial
Like many teenagers, Isabella (Bella) Snow Fraser, 15, enjoys immersing herself in action role-play games online.
News
New Study Unveils Potential Therapeutic Pathways for Aggressive Pediatric Brain Tumor
A groundbreaking study led by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and the Broad Institute of MIT and Harvard has uncovered critical insights into the biology of embryonal tumor with multilayered rosettes (ETMR), a rare and aggressive brain tumor affecting young children.
News
Novel Genomic Screening Tool Enables Precision Reverse-Engineering of Genetic Programming in Cells
Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation.
News
Kimberly Stegmaier named as Pediatric Oncology Chair at Dana-Farber
Kimberly Stegmaier, MD, was named Chair of Pediatric Oncology at Dana-Farber Cancer Institute and Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital, in an announcement made today. Her appointment is effective April 1, 2025.
News
A Vision for Health Equity in Childhood Cancer
The Dana-Farber lab of Kira Bona, MD, MPH, has uncovered an alarming reality: children from low-income households are more likely to experience cancer relapse and face lower survival rates compared to their more privileged peers, despite receiving treatment on highly standardized clinical trials at top academic centers.
News
Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a Row
U.S. News & World Report has again recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #2 pediatric cancer program in the nation in its 2024-25 Best Children's Hospitals report.
News
Dana-Farber Cancer Institute Leads the Launch of IGNITE Consortium to Eradicate Health Inequities in Pediatric Cancer Care
In a bold step toward addressing the stark disparities in pediatric cancer care, Dana-Farber Cancer Institute is taking the lead in launching IGNITE—the first national, pediatric hematology-oncology health equity research consortium.
News
Study Identifies Novel Target for Pediatric Neuroblastoma
Researchers at Dana-Farber Cancer Institute have identified a protein complex that is required for the growth of a high-risk form of childhood brain cancer called MYCN-amplified neuroblastoma.
News
Telehealth Can Significantly Reduce Greenhouse Gas Emissions Associated with Cancer Care, Study Finds
Telemedicine visits for cancer care may not only be more convenient and easier to schedule than in-person appointments, they're also better for the planet, new research by Dana-Farber Cancer Institute scientists shows.
News
Science Behind Targeted Drug for Pediatric Brain Cancer Has Dana-Farber Roots
Two separate research teams had discovered a genetic driver for the most common of childhood brain tumors called pediatric low-grade glioma.